Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with Monkeypox virus

Journal of Virology

Volumn 85, Issue 17, 2011, Pages 9176-9187

  Smith, Scott K ^a   Self, Josh ^a   Weiss, Sonja ^a   Carroll, Darin ^a   Braden, Zach ^a   Regnery, Russell L ^a   Davidson, Whitni ^a   Jordan, Robert ^b   Hruby, Dennis E ^b   Damon, Inger K ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b SIGA Technologies Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TECOVIRIMAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG POTENCY; LD 50; MONKEYPOX; NONHUMAN; ORTHOPOXVIRUS; PRAIRIE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS ISOLATION; VIRUS TITRATION;

ANAL CANAL; ANIMALS; ANTIVIRAL AGENTS; BENZAMIDES; BLOOD; DISEASE MODELS, ANIMAL; DNA, VIRAL; EYE; HUMANS; ISOINDOLES; MONKEYPOX VIRUS; OROPHARYNX; POXVIRIDAE INFECTIONS; SCIURIDAE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

ANIMALIA; CYNOMYS; MONKEYPOX VIRUS; ORTHOPOXVIRUS; VARIOLA VIRUS;

EID: 80052279730     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02173-10     Document Type: Article

References (27)

1. Berhanu, A., et al. 2009. ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. Antimicrob. Agents Chemother. 53:4999-5009.
2. Breman, J. G., and D. A. Henderson. 1998. Poxvirus dilemmas-monkeypox, smallpox, and biologic terrorism. N. Engl. J. Med. 339:556-559.
3. Breman, J. G., and D. A. Henderson. 2002. Diagnosis and management of smallpox. N. Engl. J. Med. 346:1300-1308.
4. Centers for Disease Control and Prevention. 2003. Update: multistate outbreak of monkeypox-Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morb. Mortal. Wkly. Rep. 52:642-646.
5. Chen, Z., et al. 2006. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc. Natl. Acad. Sci. U. S. A. 103:1882-1887.
6. Duraffour, S., et al. 2007. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir. Ther. 12:1205-1216.
7. Emerson, G. L., et al. 2009. The phylogenetics and ecology of the orthopoxviruses endemic to North America. PLoS One 4:e7666.
8. Huggins, J., et al. 2009. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob. Agents Chemother. 53:2620-2625.
9. Hutson, C. L., et al. 2010. Dosage comparison of Congo Basin and West African strains of monkeypox virus using a prairie dog animal model of systemic orthopoxvirus disease. Virology 402:72-82.
10. Hutson, C. L., and I. K. Damon. 2010. Monkeypox virus infections in small animal models for evaluation of anti-poxvirus agents. Viruses 2:2763-2776.
11. Hutson, C. L., et al. 2007. Monkeypox zoonotic associations: insights from laboratory evaluation of animals associated with the multi-state us outbreak. Am. J. Trop. Med. Hyg. 76:757-768.
12. Hutson, C. L., et al. 2009. A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus. J. Gen. Virol. 90:323-333.
13. Jezek, Z., A. I. Gromyko, and M. V. Szczeniowski. 1983. Human monkeypox. J. Hyg. Epidemiol. Microbiol. Immunol. 27:13-28.
14. Li, Y., V. A. Olson, T. Laue, M. T. Laker, and I. K. Damon. 2006. Detection of monkeypox virus with real-time PCR assays. J. Clin. Virol. 36:194-203.
15. Li, Y., H. Zhao, K. Wilkins, C. Hughes, and I. K. Damon. 2010. Real-time PCR assays for the specific detection of monkeypox virus West African and Congo Basin strain DNA. J. Virol. Methods 169:223-227.
16. Likos, A. M., et al. 2005. A tale of two clades: monkeypox viruses. J. Gen. Virol. 86:2661-2672.
17. Massoudi, M. S., L. Barker, and B. Schwartz. 2003. Effectiveness of postexposure vaccination for the prevention of smallpox: results of a Delphi analysis. J. Infect. Dis. 188:973-976.
18. Mortimer, P. P. 2003. Can postexposure vaccination against smallpox succeed? Clin. Infect. Dis. 36:622-629.
19. Nalca, A., et al. 2008. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res. 79:121-127.
20. Quenelle, D. C., et al. 2007. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob. Agents Chemother. 51:689-695.
21. Reed, K. D., et al. 2004. The detection of monkeypox in humans in the Western Hemisphere. N. Engl. J. Med. 350:342-350.
22. Reynolds, M. G., et al. 2006. Clinical manifestations of human monkeypox influenced by route of infection. J. Infect. Dis. 194:773-780.
23. Rimoin, A. W., et al. 2007. Endemic human monkeypox, Democratic Republic of Congo, 2001-2004. Emerg. Infect. Dis. 13:934-937.
24. Sbrana, E., et al. 2007. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am. J. Trop. Med. Hyg. 76:768-773.
25. Smith, S. K., et al. 2009. In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob. Agents Chemother. 53:1007-1012.
26. Xiao, S. Y., et al. 2005. Experimental infection of prairie dogs with monkeypox virus. Emerg. Infect. Dis. 11:539-545.
27. Yang, G., et al. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79:13139-13149.